United States Melanoma Diagnostics & Therapeutics Market

United States Melanoma Diagnostics & Therapeutics Market Analysis

The United States Melanoma Diagnostics & Therapeutics Market size is estimated at USD 3.45 billion in 2025, and is expected to reach USD 5.21 billion by 2030, at a CAGR of 8.58% during the forecast period (2025-2030).

The increasing number of melanoma cases, the emphasis on early detection and treatment, and manufacturers actively seeking regulatory approvals are expected to drive the growth of the United States melanoma diagnostics and therapeutics market.

The higher incidence of melanoma, driven by increased sun exposure and the aging population, leads to a higher demand for early detection and effective treatment. For instance, according to January 2024 stats from the American Cancer Society, approximately 100,640 new invasive melanoma cases are expected to be diagnosed in 2024, with around 59,170 cases in men and 41,470 in women. In comparison, only 89070 invasive melanoma cases were estimated to have occurred in 2023.

As per the above-mentioned source, individuals with lighter skin tones face a heightened risk for melanoma. The lifetime probabilities of developing melanoma stand at approximately 3% (1 in 33) for White individuals, 0.1% (1 in 1,000) for Black individuals, and 0.5% (1 in 200) for Hispanic individuals. Therefore, the higher incidence of melanoma drives increased demand for early detection and effective treatment, fueling the growth of the melanoma diagnostic and therapeutic market over the forecast period.

The increased likelihood of diagnosing very early-stage melanoma in screened individuals will drive the demand for biopsy devices. Early detection requires precise diagnostic tools, boosting the market for biopsy devices as healthcare providers aim to identify and treat melanoma at its earliest stages. For instance, according to data of an observational study supported by National Cancer Institute and published in May 2022, individuals who underwent skin cancer screening were more likely to be diagnosed with very early-stage melanoma compared to those who did not undergo screening. Therefore, with rising awareness, the number of screenings are anticipated to rise. Again, as healthcare providers need precise diagnostic tools to identify and treat melanoma at its earliest stages, the increasing screening is expected to positively impact the demand for melanoma diagnostics during the forecast period.

Manufacturers actively engage in marketing efforts, including receiving government approvals and forming partnerships to expand their market presence. For instance, in October 2023, Bristol Myers Squibb Company received the United States Food and Drug Administration (FDA) approval for Opdivo (nivolumab) for the adjuvant treatment of adult and pediatric patients aged 12 years and older with wholly resected stage IIB or IIC melanoma. This approval expanded the adjuvant indication for Opdivo and reinforced the company's commitment to offering treatment options for melanoma patients.

Due to the factors mentioned above, such as the growing burden of melanoma cases, rising adoption of early detection and skin cancer treatment, and manufacturers focusing on marketing approval, the market is expected to grow in the coming years.

However, the high cost associated with the therapy will significantly hinder their adoption in the forecast period.

United States Melanoma Diagnostics & Therapeutics Market Trends

The Immune Therapy Segment is Expected to Witness a Significant Growth Over the Forecast Period

Immune therapy, or immunotherapy, is a cancer treatment that enhances the body’s immune system to recognize and attack cancer cells. This approach is particularly effective in treating advanced melanoma, as it can help prevent the spread of the disease and, in some cases, provide a cure. It offers various treatment options specifically for melanoma, such as neoadjuvant immunotherapy. Neoadjuvant immunotherapy provides a promising treatment option for high-risk melanoma patients. It is an immunotherapy given before surgery to help prepare the immune system to fight and eliminate tiny cancer cells that might have spread from the primary tumor.

For instance, according to an article published in the ESMO Open Journal in May 2024, neoadjuvant immunotherapy is increasingly crucial in treating high-risk, surgically resectable melanoma patients. As per the same source, patients with high-risk melanoma face a rapidly evolving and increasingly complex landscape of immunotherapeutic treatments. Therefore, this advanced method improves patient outcomes and accelerates the development of new diagnostic and therapeutic strategies. The growing use of neoadjuvant immunotherapy increases the need for advanced diagnostic tools to assess tumor response and optimize treatment strategies.

Additionally, the Food and Drug Administration’s (FDA’s) approval of new immunotherapy options for melanoma significantly drives the market’s growth. For instance, in March 2024, the FDA approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes, or TILs. These innovative treatments, which show encouraging results, have intensified the demand for precise and prompt diagnoses. As targeted therapies become more accessible, the demand for accurate patient stratification intensifies. For instance, in March 2022, the FDA approved a new treatment for metastatic or inoperable melanoma, a severe form of skin cancer. Developed from research at the Johns Hopkins Kimmel Cancer Center, this treatment used two immunotherapy agents, relatlimab (anti-LAG-3) and nivolumab (anti-PD-1). Therefore, the growing FDA approval of immunotherapies drives the market by expanding treatment options and improving patient outcomes. As a result of this trend, investments in research and development are on the rise, leading to heightened market growth and greater awareness of melanoma treatments.

Moreover,

Hence, the adoption of neoadjuvant immunotherapy is increasing, advanced method options are growing, and manufacturers are focusing on initiatives, including FDA approval, which is expected to grow in the coming years.

The Biopsy Devices Segment is Expected to Witness a Significant Growth Over the Forecast Period

Biopsy devices are specialized tools used to extract tissue or cells from the body for assessment under a microscope. These devices help diagnose various conditions, including cancer, by allowing pathologists to analyze the sample for abnormalities. By enabling pathologists to scrutinize the extracted tissue, these devices are pivotal in diagnosing various conditions, notably cancer.

The evolving landscape of melanoma diagnosis, particularly the integration of molecular diagnostics with traditional histological methods, enhances the accuracy of detecting and staging melanoma. This advancement improves patient outcomes and increases reliance on biopsy devices, as precise diagnostics necessitate high-quality tissue sampling. For instance, an article published in Frontiers in November 2023 stated the evolving landscape of melanoma diagnosis, emphasizing the importance of molecular diagnostics alongside traditional histological methods. It highlights that new technologies, including qRT-PCR technology, can improve the accuracy of melanoma detection and staging, influencing the development and use of biopsy devices. In conclusion, the industry's shift towards advanced diagnostic techniques will drive the growth of biopsy devices as healthcare providers increasingly seek reliable tools for accurate melanoma detection and management.

Additionally, the rise in cutaneous melanoma cases strongly drives this segment's growth. For instance, according to an article published in the World Journal of Clinical Oncology in October 2022, the incidence of cutaneous melanoma is increasing, primarily due to solar radiation exposure. Clinically suspected cutaneous melanoma requires a thorough evaluation of suspected lesions using complete diagnostic excision biopsies. Thus, the rising number of cutaneous melanoma will increase the demand for biopsy devices, significantly boosting market growth as healthcare providers seek practical diagnostic tools.

Thus, factors such as the increasing incidence of melanoma, particularly cutaneous melanoma, and the integration of molecular diagnostics in biopsy devices are anticipated to drive the growth of this segment over the forecast period.

United States Melanoma Diagnostics & Therapeutics Industry Overview

The United States melanoma diagnostics & therapeutics market is moderately fragmented due to several companies operating in the region. Major players in the market are majorly focused on regulatory approval as well as product launches to expand their presence in the United States market. The competitive landscape includes analyzing companies holding the market shares, including Amgen, Inc., Bristol-Myers Squibb, F. Hoffman-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, and others.

United States Melanoma Diagnostics & Therapeutics Market Leaders

United States Melanoma Diagnostics & Therapeutics Market News

• November 2024: Replimune Group, Inc., a biotechnology company specializing in oncolytic immunotherapies, has sought FDA approval for its advanced melanoma treatment, RP1, when used alongside nivolumab. The biologics license application (BLA) was submitted through the FDA's Accelerated Approval pathway. Notably, in June 2024, the FDA awarded RP1, used alongside nivolumab, the Breakthrough Therapy designation.
• September 2024: The U.S. Food and Drug Administration granted fast-track designation to the development of VMT01, a targeted alpha-particle therapy (212Pb), for diagnosing and treating patients with unresectable or metastatic melanoma, particularly those showing melanocortin one receptor (MC1R) expression. VMT01 specifically targets tumor sites that express MC1R, a protein frequently overexpressed in metastatic melanoma, delivering the alpha-emitting isotope 212Pb.